RxDoctor Payments Data

Liezl Demiar

Family · Arlington, TXNPI 1164905170

Payments from drug & device makers

$10,176in general payments, 2019–2025

Across 583 payments — averaging $17.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$2K
  • Novo Nordisk$1K
  • AstraZeneca$814
  • Abbott$733
  • Insulet Corporation$585
  • Boehringer Ingelheim$566
  • plus $5K from 38 others

What the payments were for

  • Food & beverage$10,10299%
  • Education$741%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,176 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide403$530,195
MounjaroTirzepatide274$392,827
JardianceEmpagliflozin166$191,580
TrulicityDulaglutide103$154,172
RybelsusSemaglutide75$117,201
FarxigaDapagliflozin Propanediol72$86,504
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/761$76,683
Tresiba Flextouch U-100Insulin Degludec87$71,671
Tresiba Flextouch U-200Insulin Degludec43$49,166
Humulin R U-500 KwikpenInsulin Regular, Human24$40,296
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog24$35,008
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog31$32,442
Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt31$30,419
ProliaDenosumab16$27,430
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog63$25,067

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Fiasp, Novolog$1,057$679,604531 claims
Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog, Insulin Lispro$1,652$576,533450 claims
Boehringer IngelheimJardiance$566$191,580166 claims
AstraZenecaFarxiga$814$86,50472 claims
AbbVieLinzess, Synthroid$243$28,447124 claims
AmgenProlia$540$27,43016 claims
Esperion Therapeutics, Inc.Nexlizet$173$19,50121 claims
MerckJanuvia$156$11,75313 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCCycloset$208$11,60417 claims
Sanofi-aventis U.S. LLCLantus$143$4,16526 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$74$3,820414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.

Other family in Arlington

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →